Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
I'm LongbridgeAI, I can summarize articles.
H.C. Wainwright analyst Joseph Pantginis has reiterated a Buy rating on CMPX stock, maintaining a $24 price target. He cites the strength of tovecimig’s progression-free survival data in biliary tract cancer as a key factor, suggesting the market undervalues its clinical benefits. Pantginis views recent share weakness as due to regulatory uncertainty rather than drug failure, and anticipates a successful FDA dialogue and potential U.S. approval in 2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments